CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Long-Term Outcomes After Management of Restenosis or Thrombosis of Drug-Eluting Stents
Gregory J. Mishkel, MD, FACC*, , ,
Anna L. Moore, MPH ,
Steve Markwell, MA ,
M. Coleman Shelton and
Marc E. Shelton, MD, FACC*, , ,*
* Prairie Heart Institute at St. John's Hospital, Springfield, Illinois
Prairie Education & Research Cooperative, Springfield, Illinois
Southern Illinois University School of Medicine, Springfield, Illinois
Manuscript received February 1, 2006;
revised manuscript received August 10, 2006,
accepted August 15, 2006.
* Reprint requests and correspondence: Dr. Marc E. Shelton, Prairie Cardiovascular Consultants, Ltd., Prairie Heart Institute, P.O. Box 19420, Springfield, Illinois 62794. (Email: mshelton{at}prairieheart.com).
OBJECTIVES: The purpose of this study was to examine the outcomes of patients who developed coronary in-stent restenosis (ISR) or stent thrombosis (STH) inside drug-eluting stents (DES).
BACKGROUND: Drug-eluting stents have markedly reduced the incidence of restenosis. However, when restenosis occurs within a DES, its optimal management remains unclear.
METHODS: We retrospectively analyzed clinical and angiographic data from 92 patients who underwent revascularization for ISR (n = 84) or STH (n = 8) within a DES at our institution. Regular follow-ups were available up to 2 years. We recorded the occurrence of major adverse cardiac events (MACE), defined as deaths from all causes, myocardial infarction (MI), or target lesion revascularization (TLR), among patients treated by the "DES sandwich" technique or by other treatment methods.
RESULTS: In-hospital MACE included 1 periprocedural MI and 2 deaths. Over a mean follow-up of 15 ± 6 months, the overall rates of death, MI, and TLR were 8.7%, 2.2%, and 30.6%, respectively. By actuarial analysis, the 12-month TLR and MACE rates were 28.2% and 42.9%, respectively.
CONCLUSIONS: Current treatments of ISR or STH in DES are associated with a high long-term rate of MACE.
|
Abbreviations and Acronyms
| | BMS = bare-metal stent(ing) | | DES = drug-eluting stents | | ISR = in-stent restenosis | | MACE = major adverse cardiovascular events | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | STEMI = ST-segment elevation myocardial infarction | | STH = stent thrombosis | | TLR = target lesion revascularization |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 49: A35-A36.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
G. N. Levine, E. R. Bates, J. C. Blankenship, S. R. Bailey, J. A. Bittl, B. Cercek, C. E. Chambers, S. G. Ellis, R. A. Guyton, S. M. Hollenberg, et al.
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
J. Am. Coll. Cardiol.,
December 6, 2011;
58(24):
e44 - e122.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members, G. N. Levine, E. R. Bates, J. C. Blankenship, S. R. Bailey, J. A. Bittl, B. Cercek, C. E. Chambers, S. G. Ellis, R. A. Guyton, et al.
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Circulation,
December 6, 2011;
124(23):
e574 - e651.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Habara, K. Mitsudo, K. Kadota, T. Goto, S. Fujii, H. Yamamoto, H. Katoh, N. Oka, Y. Fuku, S. Hosogi, et al.
Effectiveness of Paclitaxel-Eluting Balloon Catheter in Patients With Sirolimus-Eluting Stent Restenosis
J. Am. Coll. Cardiol. Intv.,
February 1, 2011;
4(2):
149 - 154.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Latib, M. Mussardo, A. Ielasi, G. Tarsia, C. Godino, R. Al-Lamee, A. Chieffo, F. Airoldi, M. Carlino, M. Montorfano, et al.
Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis
J. Am. Coll. Cardiol. Intv.,
February 1, 2011;
4(2):
155 - 164.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. D. Dangas, B. E. Claessen, A. Caixeta, E. A. Sanidas, G. S. Mintz, and R. Mehran
In-Stent Restenosis in the Drug-Eluting Stent Era
J. Am. Coll. Cardiol.,
November 30, 2010;
56(23):
1897 - 1907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Teirstein
Drug-Eluting Stent Restenosis: An Uncommon Yet Pervasive Problem
Circulation,
July 6, 2010;
122(1):
5 - 7.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Alfonso
Treatment of Drug-Eluting Stent Restenosis: The New Pilgrimage: Quo Vadis?
J. Am. Coll. Cardiol.,
June 15, 2010;
55(24):
2717 - 2720.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Mehilli, R. A. Byrne, K. Tiroch, S. Pinieck, S. Schulz, S. Kufner, S. Massberg, K.-L. Laugwitz, A. Schomig, A. Kastrati, et al.
Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study
J. Am. Coll. Cardiol.,
June 15, 2010;
55(24):
2710 - 2716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Caixeta, P. Genereux, G. Dangas, and R. Mehran
Chapter 28 In-stent restenosis in the drug-eluting stent era
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
I. Sheiban, D. Sillano, G. Biondi-Zoccai, A. Chieffo, A. Colombo, S. Vecchio, M. Margheri, J. P. Gunn, T. Raina, F. Liistro, et al.
Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From a Cohort of 718 Patients: FAILS (Failure in Left Main Study)
J. Am. Coll. Cardiol.,
September 22, 2009;
54(13):
1131 - 1136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H Bhatt and T. H Hauser
Very Late Stent Thrombosis After Dual Antiplatelet Therapy Discontinuation in a Patient with a History of Acute Stent Thrombosis
Ann. Pharmacother.,
May 1, 2008;
42(5):
708 - 712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the Year in JACC 2007
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Harrington and E. M. Ohman
The Enigma of Drug-Eluting Stents: Hope, Hype, Humility, and Advancing Patient Care
JAMA,
May 9, 2007;
297(18):
2028 - 2030.
[Full Text]
[PDF]
|
 |
|
|